Allogene Therapeutics is integrating MRD testing with its off-the-shelf CAR-T therapy in the ALPHA3 trial, aiming to move intervention earlier in large B-cell lymphoma. The focus: patients after first-line therapy, where about 1 in 3 relapse.
published
Allogene Therapeutics is integrating MRD testing with its off-the-shelf CAR-T therapy in the ALPHA3 trial, aiming to move intervention earlier in large B-cell lymphoma. The focus: patients after first-line therapy, where about 1 in 3 relapse.
Latest documented BWB result
BWB member result
Exit /ES with a huge win - 56 Points or 224 ticks
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.